A Study of NK012 in Patients With Relapsed Small Cell Lung Cancer
| Status: | Archived |
|---|---|
| Conditions: | Lung Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | July 2009 |
A Phase II Study of NK012 in Sensitive Relapsed and Refractory Relapsed Small-Cell Lung Cancer (SCLC)
The purpose of this study is to determine whether NK012 is safe and effective in the
treatment of relapsed small cell lung cancer.
This is a Phase II, open label, single arm, multicenter study of NK012 in patients with
sensitive relapsed SCLC (at least 90 days since first line therapy) or refractory relapsed
SCLC (< 90 days since first line therapy). NK012 will be administered by intravenous
infusion over 30 minutes once every 28 days (on Day 1 of each cycle). Patients will be
screened for UGT1A1 polymorphism prior to enrollment.
We found this trial at
1
site
Sarah Cannon Cancer Center People who live with cancer
Click here to add this to my saved trials
